InBrain Neuroelectronics today announced $16.8 million in Series A funding for its neuroelectronic system designed to treat epilepsy and Parkinson’s disease.
The investment in the Barcelona-based company was co-led by Asabys Partners and Alta Life Sciences, and joined by Vsquared Ventures and TruVenturo GmbH. The Spanish Ministry of Science’s CDTI also participated, as did the Institut Català de Finances’ ICF Venture Tech II fund, which provided a follow-on investment.
InBrain uses graphene electrodes to enable ultra-high signal resolution. The system’s machine learning software is designed to detect therapy-specific biomarkers to deliver highly focused, adaptive neuromodulation therapy that is personalized for each patient.
The funding will be used to advance InBrain’s first-in-human clinical program, aiming to establish the safety of graphene as the new standard of care for neurotechnology devices.
“At InBrain, our mission is to improve the lives of patients with brain-related diseases, who are forced to live alone with their conditions,” said company CEO said Carolina Aguilar in a news release. “Less invasive and more intelligent neuroelectronic technologies like ours could provide safer therapies that are upgradable and adaptive in real time, to empower these patients and improve the outcomes that matter to them,”
“Graphene technology has matured and is ready for the next challenge. This investment is an important stepping stone toward our goal of transforming the way neurological disorders are treated,” added InBrain chief scientific officer Jose Garrido.